Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Precigen, Inc. before investing.

In this article, we go over a few key elements for understanding Precigen, Inc.’s stock price such as:

• Precigen, Inc.’s current stock price and volume
• Why Precigen, Inc.’s stock price changed recently
• Upgrades and downgrades for PGEN from analysts
• PGEN’s stock price momentum as measured by its relative strength

About Precigen, Inc. (PGEN)

Before we jump into Precigen, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Want to learn more about Precigen, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Precigen, Inc..

Precigen, Inc.’s Stock Price as of Market Close

As of June 03, 2026, 12:16 PM, CST, Precigen, Inc.’s stock price was $3.765.

Precigen, Inc. is down 2.46% from its previous closing price of $3.860.

During the last market session, Precigen, Inc.’s stock traded between $3.755 and $3.900. Currently, there are approximately 354.29 million shares outstanding for Precigen, Inc..

Precigen, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Precigen, Inc. Stock Price History

Precigen, Inc.’s (PGEN) price is currently down 13.25% so far this month.

During the month of June, Precigen, Inc.’s stock price has reached a high of $4.400 and a low of $3.755.

Over the last year, Precigen, Inc. has hit prices as high as $5.465 and as low as $1.280. Year to date, Precigen, Inc.’s stock is down 9.93%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Precigen, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 02, 2026, there were 2 analysts who downgraded Precigen, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Precigen, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Precigen, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Precigen, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Precigen, Inc. (PGEN) by visiting AAII Stock Evaluator.

Relative Price Strength of Precigen, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 02, 2026, Precigen, Inc. has a weighted four-quarter relative price strength of 39.30%, which translates to a Momentum Score of 96 and is considered to be Very Strong.

Want to learn more about how Precigen, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Precigen, Inc. Stock Price: Bottom Line

As of June 3, 2026, Precigen, Inc.’s stock price is $3.765, which is down 2.46% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Precigen, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.